EGFR and non-small cell lung carcinoma: During the last two decades, the development and clinical application of EGFR tyrosine kinase inhibitors (EGFR-TKIs), namely the first-generation gefitinib, erlotinib, and icotinib; the second-generation afatinib and dacomitinib; and the third-generation osimertinib, have been associated with substantial responses and survival benefit in patients harboring EGFR mutations, paving the way for establishing a precision oncology approach regarding NSCLC [3].